Results 1 to 10 of about 581 (108)

Sonidegib en el tratamiento del carcinoma basocelular localmente avanzado

Actas Dermo-Sifiliográficas, 2021
Resumen: Sonidegib es un inhibidor del receptor transmembrana Smoothened (SMO), de la vía de señalización de Hedgehog, indicado para el tratamiento del carcinoma basocelular localmente avanzado (CBCla), no susceptible a cirugía curativa ni a radioterapia.
O. Sanmartín, B. Llombart, G. Carretero Hernández, Á. Flórez Menéndez, R. Botella-Estrada, E. Herrera Ceballos, S. Puig   +6 more
doaj   +4 more sources

[Artículo traducido] Sonidegib para el tratamiento del carcinoma basocelular avanzado en práctica clínica real: estudio nacional multicéntrico

Actas Dermo-Sifiliográficas, 2023
Resumen: Antecedentes: El carcinoma de células basales (CBC) es el cáncer más prevalente. Una minoría de CBC tiene un comportamiento agresivo (CBCla) y puede requerir inhibidores de la vía hedgehog, como sonidegib como tratamiento.
O.M. Moreno-Arrones, S. Béa-Ardebol, F. Mayo-Martinez, G. Pérez-Pastor, I. Torres-Navarro, M. Bonfill-Ortí, G. Deza, V. Ruiz-Salas, E. Masferrer, C. Feal, L. Turrión-Merino, A. Toll, M. Yébenes, S. Galiano-Mejías, A. Jaka, C. Ferrandiz-Pulido, A. Florez, N. Hernández-Hernández, R. Fernández-de-Misa, L. Rios-Buceta, O. Sanmartin   +20 more
doaj   +4 more sources

Benefit–risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma [PDF]

Drugs in Context, 2022
Background: Sonidegib and vismodegib are Hedgehog pathway inhibitors (HhIs) that play a relevant role in the management of locally advanced basal cell carcinoma (laBCC).
Antonio J García Ruiz, Nuria García-Agua Soler, Enrique Herrera Acosta, Iris Zalaudek, Josep Malvehy   +4 more
doaj   +2 more sources

Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study [PDF]

Actas Dermo-Sifiliográficas, 2023
Background: Basal cell carcinoma (BCC) is the most prevalent cancer. A minority of BCCs have an aggressive behaviour (laBCC) and may require hedgehog pathway inhibitors such as sonidegib as its treatment.
O.M. Moreno-Arrones, S. Béa-Ardebol, F. Mayo-Martinez, G. Pérez-Pastor, I. Torres-Navarro, M. Bonfill-Ortí, G. Deza, V. Ruiz-Salas, E. Masferrer, C. Feal, L. Turrión-Merino, A. Toll, M. Yébenes, S. Galiano-Mejías, A. Jaka, C. Ferrandiz-Pulido, A. Florez, N. Hernández-Hernández, R. Fernández-de-Misa, L. Rios-Buceta, O. Sanmartin   +20 more
doaj   +3 more sources

Sonidegib, a Novel Inhibitor of Suicidal Erythrocyte Death

Cellular Physiology and Biochemistry, 2018
Background/Aims: The Hedgehog pathway disrupting drug sonidegib is used in the treatment of basal cell carcinoma. Side effects of sonidegib include anemia, which could result either from impaired erythropoiesis or from loss of erythrocytes e.g.
Abdulla Al Mamun Bhuyan, Itishri Sahu, Hang Cao, Florian Lang   +3 more
doaj   +2 more sources

Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease

Blood Advances, 2017
: Hedgehog signaling plays a key role in tissue fibrosis, the pathological hallmark of chronic graft-versus-host disease (cGVHD). We conducted a phase 1 trial of sonidegib, a selective antagonist of the hedgehog coreceptor Smoothened, for the treatment ...
Zachariah DeFilipp, Rosalynn M. Nazarian, Areej El-Jawahri, Shuli Li, Jami Brown, Candice Del Rio, Melissa Smith, Betsy Valles, Karen K. Ballen, Steven L. McAfee, Jacalyn Rosenblatt, Joseph H. Antin, Corey S. Cutler, Yi-Bin Chen   +13 more
doaj   +2 more sources

Tolerance of sonidegib after intolerance of vismodegib—Experience in two patients with nevoid basal cell carcinoma syndrome (Gorlin syndrome)

Skin Health and Disease, 2023
Nevoid basal cell carcinoma syndrome (NBCCS, Gorlin syndrome) is a rare genetic condition characterized by the early development of numerous cutaneous basal cell carcinomas (BCCs).
Federico Venturi, Luciana Trane, Flavia Silvestri, Biancamaria Zuccaro, Elisabetta Magnaterra, Vincenzo De Giorgi   +5 more
doaj   +3 more sources

Sonidegib reduced tumor burden in patients with advanced basal cell carcinoma in the BOLT trial: Long-term analysis results

EJC Skin Cancer
Background: The Hedgehog inhibitor sonidegib had durable efficacy and a manageable safety profile in patients with locally advanced basal cell carcinoma (laBCC) through 42 months of the BOLT trial.
Michael R. Migden, Aaron S. Farberg, James Spencer, Felix Kiecker, Alexander Guminski, Kurt Gebauer, Carmen Loquai, Caroline Robert, Reinhard Dummer, Dirk Schadendorf, Axel Hauschild, Jean Jacques Grob, Nicholas Squittieri, Ramon Arntz, Serena Martelli, Joerg Dierlamm, Ralf Gutzmer   +16 more
doaj   +3 more sources

Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study

Acta Dermato-Venereologica, 2022
Sonidegib, a hedgehog pathway inhibitor, is indicated for treatment of locally advanced basal cell carcinoma, based on the results of the BOLT study. However, to date, no real-world study of sonidegib has been reported.
Florian Herms, Barouyr Baroudjian, Julie Delyon, Pauline Laly, Pauline Tetu, Celeste Lebbe, Nicole Basset-Seguin   +6 more
doaj   +1 more source

Experience with sonidegib in patients with advanced basal cell carcinoma: case reports

Drugs in Context, 2022
Sonidegib is a Hedgehog signalling pathway inhibitor approved for use in patients with advanced basal cell carcinoma (BCC) not eligible for surgery or radiotherapy.
Susana Puig, Carlos Serra-Guillén, Gemma Pérez-Pastor, Álvaro Martínez-Domenech, Ricardo Fernández-de-Misa Cabrera   +4 more
doaj   +1 more source